نتایج جستجو برای: dipeptidyl peptidase iv

تعداد نتایج: 187377  

Journal: :Frontiers in Physiology 2020

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1998
J Lin P J Toscano J T Welch

Dipeptidyl peptidase IV (EC 3.4.14.5; DPP IV), also known as the leukocyte differentiation antigen CD26 when found as an extracellular membrane-bound proline specific serine protease, cleaves a dipeptide from the N terminus of a polypeptide chain containing a proline residue in the penultimate position. Here we report that known (Z)-Ala-psi[CF=C]-Pro dipeptide isosteres 1 and 2, which contain O...

Journal: :Hypertension 2008
Edwin K Jackson Zaichuan Mi

Dipeptidyl peptidase IV converts neuropeptide Y(1-36) (Y(1)-receptor agonist released from renal sympathetic nerves) to neuropeptide Y(3-36) (selective Y(2)-receptor agonist). Previous studies suggest that Y(1), but not Y(2), receptors enhance renovascular responses to angiotensin II in kidneys from genetically-susceptible animals. Therefore, we hypothesized that inhibition of dipeptidyl peptid...

2005
Elaine M. Sinclair Daniel J. Drucker

Purpose of review Current treatments for type 2 diabetes are effective, but a substantial number of patients continue to have difficulty in achieving and maintaining satisfactory control of blood glucose. The available data suggest that enhancing the action of glucagon-like peptide 1 through the use of glucagon-like peptide 1 receptor agonists, or by preventing the degradation of glucagon-like ...

Journal: :Chemical communications 2016
Yi Wang Xueli Wu Yiyu Cheng Xiaoping Zhao

A novel fluorescent probe for in vitro and in vivo imaging of dipeptidyl peptidase-4 (DPP-4) was designed and synthesized. This probe is successfully utilized to screen DPP-4 inhibitors in living 3T3-L1 cells and zebrafish, which provides a novel approach for the discovery of anti-diabetes drugs.

2018
Dandan Zhao Shaoqian Zhao Xiao Wang Mingbo Su Wen Liu Qinyun Ma Jie Hong Weiqiong Gu Jingya Li Ruixin Liu Guang Ning Jiqiu Wang Yifei Zhang

The clinical application of dipeptidyl peptidase IV inhibitors (DPP4i) increasing active glucagon-like peptide-1 (AGLP-1) levels has been linked to pancreatitis, pancreatic tumors, and cardiovascular events. However, DPP4 mutations in humans or the long-term outcomes of high glucagon-like peptide-1 (GLP-1) level exposure have not been reported. A trio family with a proband showing an extremely ...

Journal: :Biochemical Society transactions 1976
A J Kenny A G Booth E J Wood A R Young

Dipeptidyl peptidase IV was first described by Hopsu-Havu & Glenner (1966) and purified from kidney by Hopsu-Havu et al. (1968). Enzymes of this class (for a review, see McDonald et al., 1971) hydroylse dipeptides from the N-terminus of susceptible substrates. Barth et al. (1974) demonstrated that dipeptidyl peptidase IV exhibits two specificities, involving substrates of the types X-Pro-Y and ...

Journal: :Clinical chemistry 1987
M Hagihara M Ohhashi T Nagatsu

We examined the activities of peptidases in plasma and tissues of the New Zealand Black (NZB) mouse as an animal model of human systemic lupus erythematosus, and also in serum from patients with rheumatoid arthritis and systemic lupus erythematosus. Activities of dipeptidyl peptidase II (DAP II) and post-proline cleaving enzyme (PPCE) were increased, and dipeptidyl peptidase IV (DAP IV) activit...

2013
Richard H. Gomer Sarah E. Herlihy Darrell Pilling Anu S. Maharjan

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید